Biomarkers have emerged as an important tool in drug development process during both the preclinical and clinical phases of candidate compound evaluation. Given the number and overall complexity of available biomarkers on the market, the determination of which biomarkers to evaluate can at times be challenging. In conjunction with board-certified pathologists and toxicologists, MPI Research has committed to developing panels of assays designed to meet your specific study needs, while fulfilling regulatory requirements. Our highly knowledgeable team has experience in the development of the following biomarkers
To inquire about additional biomarkers not listed or speak to one of our experts, please contact us today at firstname.lastname@example.org.